Genmab A/S
NASDAQ:GMAB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17.98
35.34
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| DK |
|
Genmab A/S
CSE:GMAB
|
127.8B DKK |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.8B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.5B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -5 981.6% |
| 30th Percentile | 1.3% |
| Median | 7.5% |
| 70th Percentile | 16.3% |
| Max | 423.3% |
Other Profitability Ratios
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Genmab A/S is 36.8%, which is above its 3-year median of 35.3%.
Over the last 3 years, Genmab A/S’s Operating Margin has increased from 36.8% to 36.8%. During this period, it reached a low of 31.6% on Jun 30, 2024 and a high of 43.5% on Dec 31, 2022.